- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in Alzheimer’s Disease Drug Development
Authors
Keywords
Alzheimer’s disease, Beta-amyloid, Clinical trials
Journal
BMC Medicine
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-03-25
DOI
10.1186/s12916-015-0297-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: ACC-001 Clinical Trials Are Ongoing
- (2017) J. Michael Ryan et al. JOURNAL OF ALZHEIMERS DISEASE
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CRENEZUMAB IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE
- (2014) Jeffrey Cummings et al. Alzheimers & Dementia
- A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease
- (2014) Michael S. Rafii et al. Alzheimers & Dementia
- Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
- (2014) Aaron H Burstein et al. BMC Neurology
- Tau PET Imaging in Alzheimer’s Disease
- (2014) Nobuyuki Okamura et al. Current Neurology and Neuroscience Reports
- Clinical trial of an inhibitor of RAGE-A interactions in Alzheimer disease
- (2014) D. Galasko et al. NEUROLOGY
- Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
- (2014) Rachelle S. Doody et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid
- (2013) Heiko Braak et al. ACTA NEUROPATHOLOGICA
- The worldwide economic impact of dementia 2010
- (2013) Anders Wimo et al. Alzheimers & Dementia
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
- (2013) Clifford R Jack et al. LANCET NEUROLOGY
- Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease
- (2013) Nicholas Kozauer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study
- (2012) Bengt Winblad et al. LANCET NEUROLOGY
- A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
- (2012) Thorlakur Jonsson et al. NATURE
- Down's syndrome and Alzheimer's disease: towards secondary prevention
- (2012) Seth Ness et al. NATURE REVIEWS DRUG DISCOVERY
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease
- (2011) Clifford R. Jack et al. ANNALS OF NEUROLOGY
- Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease
- (2011) Benjamin W Miller et al. ANNALS OF PHARMACOTHERAPY
- EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors
- (2011) Jos Prickaerts et al. NEUROPHARMACOLOGY
- Alzheimer's Disease
- (2011) D. J. Selkoe Cold Spring Harbor Perspectives in Biology
- Can Alzheimer disease be prevented by amyloid-β immunotherapy?
- (2010) Cynthia A. Lemere et al. Nature Reviews Neurology
- Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
- (2010) Christopher C. Rowe et al. NEUROBIOLOGY OF AGING
- Tau-Focused Immunotherapy for Alzheimers Disease and Related Tauopathies
- (2009) Einar Sigurdsson Current Alzheimer Research
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started